Literature DB >> 31182781

The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma.

Sophia Adamia1, Ivane Abiatari2, Samir B Amin3, Mariateresa Fulciniti1, Stephane Minvielle4, Cheng Li5, Philippe Moreau4, Herve Avet-Loiseau6, Nikhil C Munshi7, Kenneth C Anderson8.   

Abstract

Over the last few years, a detailed map of genetic and epigenetic lesions that underlie multiple myeloma (MM) has been created. Regulation of microRNA (miR)-dependent gene expression and mRNA splicing play significant roles in MM pathogenesis; however, to date an interplay between these processes is not yet delineated. Here we investigated miR-mediated regulation of splicing networks at the transcriptome level. Our studies show that a significant number (78%) of miRs which are either up- or down-regulated in patient CD138+ MM cells, but not in healthy donors (HD) CD138+ plasma cells (PC), target genes involved in early stages of pre-mRNA splicing. We also identified deregulated miRs that target core splicing factors (SF) and modifiers (SM, enhancers/silencers) which cause altered splicing in MM. Our studies suggest that Let-7f, in combination other miRs which are frequently and significantly deregulated in patients with overt MM, targets genes that regulate intron excision. Importantly, deregulated expression of certain miRs in MM promote increased intron retention, a novel characteristic of the MM genome, by inducing deregulated expression of the genes that regulate the splicing network. Our studies, therefore, provide the rationale for therapeutically targeting deregulated miRs to reverse aberrant splicing and improve patient outcome in MM.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31182781      PMCID: PMC6901818          DOI: 10.1038/s41375-019-0498-5

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  50 in total

1.  ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma.

Authors:  Matteo Marchesini; Yamini Ogoti; Elena Fiorini; Anil Aktas Samur; Luigi Nezi; Marianna D'Anca; Paola Storti; Mehmet Kemal Samur; Irene Ganan-Gomez; Maria Teresa Fulciniti; Nipun Mistry; Shan Jiang; Naran Bao; Valentina Marchica; Antonino Neri; Carlos Bueso-Ramos; Chang-Jiun Wu; Li Zhang; Han Liang; Xinxin Peng; Nicola Giuliani; Giulio Draetta; Karen Clise-Dwyer; Hagop Kantarjian; Nikhil Munshi; Robert Orlowski; Guillermo Garcia-Manero; Ronald A DePinho; Simona Colla
Journal:  Cancer Cell       Date:  2017-06-29       Impact factor: 31.743

2.  MicroRNA Dysregulation to Identify Novel Therapeutic Targets.

Authors:  Carlo M Croce
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

3.  High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2.

Authors:  Yiming Zhou; Lijuan Chen; Bart Barlogie; Owen Stephens; Xiaosong Wu; David R Williams; Marie-Astrid Cartron; Frits van Rhee; Bijay Nair; Sarah Waheed; Mauricio Pineda-Roman; Yazan Alsayed; Elias Anaissie; John D Shaughnessy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

Review 4.  Genomics of Multiple Myeloma.

Authors:  Sebastien Robiou du Pont; Alice Cleynen; Charlotte Fontan; Michel Attal; Nikhil Munshi; Jill Corre; Hervé Avet-Loiseau
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

Review 5.  Roles of small RNAs in tumor formation.

Authors:  Gianpiero Di Leva; Carlo M Croce
Journal:  Trends Mol Med       Date:  2010-05-20       Impact factor: 11.951

Review 6.  Multiple myeloma.

Authors:  Shaji K Kumar; Vincent Rajkumar; Robert A Kyle; Mark van Duin; Pieter Sonneveld; María-Victoria Mateos; Francesca Gay; Kenneth C Anderson
Journal:  Nat Rev Dis Primers       Date:  2017-07-20       Impact factor: 52.329

Review 7.  Causes and consequences of microRNA dysregulation in cancer.

Authors:  Carlo M Croce
Journal:  Nat Rev Genet       Date:  2009-10       Impact factor: 53.242

8.  Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.

Authors:  Molly Went; Amit Sud; Asta Försti; Britt-Marie Halvarsson; Niels Weinhold; Scott Kimber; Mark van Duin; Gudmar Thorleifsson; Amy Holroyd; David C Johnson; Ni Li; Giulia Orlando; Philip J Law; Mina Ali; Bowang Chen; Jonathan S Mitchell; Daniel F Gudbjartsson; Rowan Kuiper; Owen W Stephens; Uta Bertsch; Peter Broderick; Chiara Campo; Obul R Bandapalli; Hermann Einsele; Walter A Gregory; Urban Gullberg; Jens Hillengass; Per Hoffmann; Graham H Jackson; Karl-Heinz Jöckel; Ellinor Johnsson; Sigurður Y Kristinsson; Ulf-Henrik Mellqvist; Hareth Nahi; Douglas Easton; Paul Pharoah; Alison Dunning; Julian Peto; Federico Canzian; Anthony Swerdlow; Rosalind A Eeles; ZSofia Kote-Jarai; Kenneth Muir; Nora Pashayan; Jolanta Nickel; Markus M Nöthen; Thorunn Rafnar; Fiona M Ross; Miguel Inacio da Silva Filho; Hauke Thomsen; Ingemar Turesson; Annette Vangsted; Niels Frost Andersen; Anders Waage; Brian A Walker; Anna-Karin Wihlborg; Annemiek Broyl; Faith E Davies; Unnur Thorsteinsdottir; Christian Langer; Markus Hansson; Hartmut Goldschmidt; Martin Kaiser; Pieter Sonneveld; Kari Stefansson; Gareth J Morgan; Kari Hemminki; Björn Nilsson; Richard S Houlston
Journal:  Nat Commun       Date:  2018-09-13       Impact factor: 14.919

9.  Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Authors:  Niccolo Bolli; Hervé Avet-Loiseau; David C Wedge; Peter Van Loo; Ludmil B Alexandrov; Inigo Martincorena; Kevin J Dawson; Francesco Iorio; Serena Nik-Zainal; Graham R Bignell; Jonathan W Hinton; Yilong Li; Jose M C Tubio; Stuart McLaren; Sarah O' Meara; Adam P Butler; Jon W Teague; Laura Mudie; Elizabeth Anderson; Naim Rashid; Yu-Tzu Tai; Masood A Shammas; Adam S Sperling; Mariateresa Fulciniti; Paul G Richardson; Giovanni Parmigiani; Florence Magrangeas; Stephane Minvielle; Philippe Moreau; Michel Attal; Thierry Facon; P Andrew Futreal; Kenneth C Anderson; Peter J Campbell; Nikhil C Munshi
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

10.  Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.

Authors:  Jonathan S Mitchell; Ni Li; Niels Weinhold; Asta Försti; Mina Ali; Mark van Duin; Gudmar Thorleifsson; David C Johnson; Bowang Chen; Britt-Marie Halvarsson; Daniel F Gudbjartsson; Rowan Kuiper; Owen W Stephens; Uta Bertsch; Peter Broderick; Chiara Campo; Hermann Einsele; Walter A Gregory; Urban Gullberg; Marc Henrion; Jens Hillengass; Per Hoffmann; Graham H Jackson; Ellinor Johnsson; Magnus Jöud; Sigurður Y Kristinsson; Stig Lenhoff; Oleg Lenive; Ulf-Henrik Mellqvist; Gabriele Migliorini; Hareth Nahi; Sven Nelander; Jolanta Nickel; Markus M Nöthen; Thorunn Rafnar; Fiona M Ross; Miguel Inacio da Silva Filho; Bhairavi Swaminathan; Hauke Thomsen; Ingemar Turesson; Annette Vangsted; Ulla Vogel; Anders Waage; Brian A Walker; Anna-Karin Wihlborg; Annemiek Broyl; Faith E Davies; Unnur Thorsteinsdottir; Christian Langer; Markus Hansson; Martin Kaiser; Pieter Sonneveld; Kari Stefansson; Gareth J Morgan; Hartmut Goldschmidt; Kari Hemminki; Björn Nilsson; Richard S Houlston
Journal:  Nat Commun       Date:  2016-07-01       Impact factor: 14.919

View more
  5 in total

1.  MicroRNA-27 Inhibits Autophagy and Promotes Proliferation of Multiple Myeloma Cells by Targeting the NEDD4/Notch1 Axis.

Authors:  Feifei Che; Jiao Chen; Chunqian Wan; Xiaobing Huang
Journal:  Front Oncol       Date:  2020-11-11       Impact factor: 6.244

2.  Downregulation of microRNA‑25‑3p inhibits the proliferation and promotes the apoptosis of multiple myeloma cells via targeting the PTEN/PI3K/AKT signaling pathway.

Authors:  Youmei Zi; Yingzi Zhang; Yanwei Wu; Lina Zhang; Ru Yang; Yan Huang
Journal:  Int J Mol Med       Date:  2021-01-15       Impact factor: 4.101

3.  Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.

Authors:  Sophia Adamia; Shruti Bhatt; Kenneth Wen; Zuzana Chyra; Geoffrey G Fell; Yu-Tzu Tai; Marisa S Pioso; Ivane Abiatari; Anthony Letai; David M Dorfman; Teru Hideshima; Kenneth C Anderson
Journal:  Leukemia       Date:  2022-01-27       Impact factor: 12.883

4.  Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment.

Authors:  Debora Soncini; Claudia Martinuzzi; Pamela Becherini; Elisa Gelli; Samantha Ruberti; Katia Todoerti; Luca Mastracci; Paola Contini; Antonia Cagnetta; Antonella Laudisi; Fabio Guolo; Paola Minetto; Maurizio Miglino; Sara Aquino; Riccardo Varaldo; Daniele Reverberi; Matteo Formica; Mario Passalacqua; Alessio Nencioni; Antonino Neri; Mehmet K Samur; Nikhil C Munshi; Mariateresa Fulciniti; Roberto M Lemoli; Michele Cea
Journal:  Haematologica       Date:  2022-06-01       Impact factor: 11.047

5.  Solamargine induces autophagy-mediated apoptosis and enhances bortezomib activity in multiple myeloma.

Authors:  Qiaoyan Han; Hua Bai; Yong Xu; Min Zhou; He Zhou; Xiaoqing Dong; Bing Chen
Journal:  Clin Exp Pharmacol Physiol       Date:  2022-03-31       Impact factor: 2.963

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.